Ornopia, Linda B.
HRN: 04-18-32 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/29/2022
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/29/2022
11/04/2022
IV
500 Mg
Q8H
Intestinal Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes